72
Jones AP, Wallis C (2010) Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 3:1–66
Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, Inoue K, Park S, Jang Y, Lee JH
(2008) Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res
31:1583–1588
Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R,
Chuang FYS, Bold RJ, Kung HJ (2009) Arginine deiminase as a novel therapy for prostate
cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700–708
Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T (2015) A single-dose of
oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep 5:1–7
Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM (2011) Polyethylene
glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard
agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a
Children’s oncology group study (Pog 8866). J Pediatr Hematol Oncol 33:610–616
Lampe BJ, English JC (2016) Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food Chem Toxicol 88:87–99
Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, Rice GM, Dorenbaum
A, Neuenburg JK, Musson DG, Gu Z, Sile S (2014) Single-dose, subcutaneous recombinant
phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 384:37–44
McCallon SK, Weir D, Lantis JC (2014) Optimizing wound bed preparation with collagenase
enzymatic debridement. The Journal of the American College of Clinical Wound Specialists
6:14–23
Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek
S, Germain DP (2010) Fabry disease: a review of current management strategies. Q J Med
103:641–659
Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A (1994) Intestinal
absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem 20:101–108
Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D (2003)
Recombinant human microplasmin: production and potential therapeutic properties. J Thromb
Haemost 1:307–313
Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses.
Journal of Clinical Pharmacology and Therapeutics 39:215–224
Pan R, Zhang ZJ, He RQ, Pan R, Zhang ZJ, He RQ (2010) Earthworm Protease. Applied and
Environmental Soil Science 2010:e294258
Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E,
Seeburg PH, Heyneker HL, Goeddel DV, Collen D (1983) Cloning and expression of human
tissue-type plasminogen activator cDNA in E. coli. Nature 301:214–221
Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ,
Merricks EP, Nichols TC, Bitonti AJ (2010) Prolonged activity of factor IX as a monomeric fc
fusion protein. Blood 115:2057–2064
Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF (2013) Biochemical
and functional characterization of a recombinant monomeric factor VIII-fc fusion protein.
J Thromb Haemost 11:132–141
Shan L, Marti T, Sollid LM, Gray GM, Khosla C (2004) Comparative biochemical analysis of
three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 383:311–318
Shapira E, Giladi A, Neuman Z (1973) Use of water-insoluble papain (WIP) for debridement of
burn eschar and necrotic tissue. Preliminary report. Plast Reconstr Surg 52:279–281
Sherwood RF, Melton RG, Alwan SM, Hughes P (1985) Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method.
Eur J Biochem 148:447–453
Smalling RW (1996) Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 78:2–7
S.S. Kumar and S. Abdulhameed
Jones AP, Wallis C (2010) Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 3:1–66
Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, Inoue K, Park S, Jang Y, Lee JH
(2008) Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res
31:1583–1588
Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R,
Chuang FYS, Bold RJ, Kung HJ (2009) Arginine deiminase as a novel therapy for prostate
cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700–708
Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T (2015) A single-dose of
oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep 5:1–7
Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM (2011) Polyethylene
glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard
agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a
Children’s oncology group study (Pog 8866). J Pediatr Hematol Oncol 33:610–616
Lampe BJ, English JC (2016) Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food Chem Toxicol 88:87–99
Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, Rice GM, Dorenbaum
A, Neuenburg JK, Musson DG, Gu Z, Sile S (2014) Single-dose, subcutaneous recombinant
phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 384:37–44
McCallon SK, Weir D, Lantis JC (2014) Optimizing wound bed preparation with collagenase
enzymatic debridement. The Journal of the American College of Clinical Wound Specialists
6:14–23
Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek
S, Germain DP (2010) Fabry disease: a review of current management strategies. Q J Med
103:641–659
Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A (1994) Intestinal
absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem 20:101–108
Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D (2003)
Recombinant human microplasmin: production and potential therapeutic properties. J Thromb
Haemost 1:307–313
Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses.
Journal of Clinical Pharmacology and Therapeutics 39:215–224
Pan R, Zhang ZJ, He RQ, Pan R, Zhang ZJ, He RQ (2010) Earthworm Protease. Applied and
Environmental Soil Science 2010:e294258
Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E,
Seeburg PH, Heyneker HL, Goeddel DV, Collen D (1983) Cloning and expression of human
tissue-type plasminogen activator cDNA in E. coli. Nature 301:214–221
Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ,
Merricks EP, Nichols TC, Bitonti AJ (2010) Prolonged activity of factor IX as a monomeric fc
fusion protein. Blood 115:2057–2064
Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF (2013) Biochemical
and functional characterization of a recombinant monomeric factor VIII-fc fusion protein.
J Thromb Haemost 11:132–141
Shan L, Marti T, Sollid LM, Gray GM, Khosla C (2004) Comparative biochemical analysis of
three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 383:311–318
Shapira E, Giladi A, Neuman Z (1973) Use of water-insoluble papain (WIP) for debridement of
burn eschar and necrotic tissue. Preliminary report. Plast Reconstr Surg 52:279–281
Sherwood RF, Melton RG, Alwan SM, Hughes P (1985) Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method.
Eur J Biochem 148:447–453
Smalling RW (1996) Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 78:2–7
S.S. Kumar and S. Abdulhameed